Trillium Therapeutics

Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company. It focuses on the immune system and its regulation. The company specializes in the discovery and development of protein therapeutics, such as monoclonal antibodies, secreted proteins, and peptides. It involves in therapeutic areas, including autoimmune disease, cancer, necrotizing enterocolitis, and transplantation. Trillium Therapeutics Inc. was formerly known as Transplantation Technologies Inc. and changed its name in May 2003. The company was founded in 1996 and is based in Toronto, Canada.

Beam Global

Blink Charging

Bit Digital, Inc

Cardiff Oncology

Marathon Digital Holdings

Novavax

Riot Blockchain

Vaxart

Biotech, bitcoin, and renewable energy led the way.

The 10 Best-Performing Stocks of 2020

The company's long-term plan is to challenge conventional cancer therapy.

The Worst Mistake Trillium Investors Can Make Right Now

This clinical-stage biotech stock could be a top buyout candidate in 2021.

My Favorite Biotech Stock for 2021

Nano-X Imaging

Teladoc

Find out what these healthcare businesses can do to deliver big gains this year.

3 Healthcare Stocks That Could Soar In 2021

Genprex

The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf (NASDAQ: IBB) outperforming the S&P 500 Index. This defensive sector also benefited from opportunity in the form of SARS-CoV-2, the virus that causes COVID-19.

5 Biotech Stocks That Generated 1,000%+ Returns In 2020

Investors need to pay close attention to Trillium (TRIL) stock based on the movements in the options market lately.

Implied Volatility Surging for Trillium (TRIL) Stock Options

A decline in the stock price plus positive clinical data equals opportunity.

Could Trillium Fall Below $10 in 2021?

BioNTech SE

Celldex Therapeutics

Co-Diagnostics

Seres Therapeutics

Moderna

Nestle SA

The highest performers of the year are biotechs fighting COVID-19 and cancer. Are they still buys for 2021?

These Were the 10 Best Healthcare Stocks of 2020

Trillium Therapeutics (TRIL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Trillium Therapeutics (TRIL) Looks Good: Stock Adds 5.8% in Session

The micro-cap has shot up an incredible 1,400% this year.

How Did Trillium Stock Perform in 2020?

A new CEO and prioritization of research could have more big gains in store for the company

Did You Miss Out on a 5000% Gain With Trillium Stock?

CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ( “ Trillium ” or the “ Company ” ) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, recently presented at the American Society of Hematology (ASH) Annual Meeting, taking place virtually from December 5-8, 2020, and provides guidance for 2021.

Trillium Therapeutics Presented Clinical Data at the 62nd ASH Annual Meeting and Provides Guidance for 2021

Five Prime Therapeutics

Mersana Therapeutics

Surface Oncology Inc

Biotech investors had more than just vaccines to think about this year.

These Were the 5 Best Cancer Stocks Of 2020

Investors are catching on to the opportunity for this innovative cancer therapy, and so is big pharma.

This Biotech Is Up 1,500% This Year. Can It Make You Rich in 2021?

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the presentation of clinical data at the upcoming American Society of Hematology (ASH) Annual Meeting, which is being held virtually from December 5-8, 2020.

Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting

CAMBRIDGE, Ma., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the nine months ended September 30, 2020.

Trillium Therapeutics Reports Third Quarter 2020 Financial and Operating Results

Trillium Therapeutics has an encouraging pipeline with key differentiators that have attracted recent investor interest. The 2 major candidates, TTI-621 & 622 have shown monotherapy activity in a breadth of haematologic cancers as CD47 targeting drugs.

Trillium Therapeutics: Investors To See Further Upside Via CD47 Focus

Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board

Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors

Adaptimmune Therapeutics

Adaptimmune Therapeutics and Trillium Therapeutics could be big winners for early shareholders.

2 Cancer Stocks That Could Make You Filthy Rich

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ( “ Trillium ” or the “ Company ” ) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of Ingmar Bruns, M.D., Ph.D. as Chief Medical Officer, effective immediately. Dr. Bruns will succeed Dr. Yaping Shou, who has elected to resign to pursue new opportunities. Dr. Shou will remain with the Company, in a consulting position, to assist with the transition.

Trillium Therapeutics Appoints Dr. Ingmar Bruns as Chief Medical Officer

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the formation of a Scientific Advisory Board (“SAB”), including Karen Ferrante, MD, Gordon Freeman, PhD, Tom Reynolds, MD, PhD, Steven Rosen, MD, and Jeff Settleman, PhD.

Trillium Therapeutics Announces Formation of Scientific Advisory Board

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that it has received Notices of Allowance from the United States Patent and Trademark Office for two patent applications covering the use of SIRPaFc for the treatment of cancer, U.S. Patent Application No. 13/320,629 (the “629 Application”, exclusively licensed to Trillium) and U.S. Patent Application No. 15/962,540 (the “540 Application”). Trillium has two SIRPaFc biologics, TTI-621 and TTI-622, in clinical development. Both therapeutics target CD47, a “don’t eat me” signal that cancer cells use to evade immune destruction.

Trillium Therapeutics Receives Notices of Allowance From U.S. Patent and Trademark Office

Are Options Traders Betting on a Big Move in Trillium (TRIL) Stock?

Industry Veteran Brings Deep Biologics Manufacturing Experience to Trillium Board Industry Veteran Brings Deep Biologics Manufacturing Experience to Trillium Board

Trillium Therapeutics Appoints Michael Kamarck, Ph.D., to Its Board of Directors

CAMBRIDGE, Mass., Sept.  16, 2020  (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of common shares of the Company at a public offering price of US$13.00 per common share (the “Offering”). 11,500,000 common shares were sold in the Offering, including the full exercise by the underwriters of their option to purchase up to an additional 1,500,000 common shares.

News for Trillium Therapeutics Stock (TRIL)